ICH E14: A New Regulatory Guidance on the Clinical Evaluation of QT/QTc Internal Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sanguinetti, M. C., Jiang, C., Curran, M. E., & Keating, M. T. (1995) · Cell · doi:10.1016/0092-8674(95)90340-2 · Cited by 2,423
Drug-induced prolongation of the QT interval
Roden, D. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032426 · Cited by 1,965
International Conference on Harmonisation
Guy, R. C. (2014) · Encyclopedia of Toxicology · doi:10.1016/b978-0-12-386454-3.00861-7 · Cited by 1,478
Drug induced QT prolongation and torsades de pointes
Yap, Y. G., & Camm, A. J. (2003) · Heart · doi:10.1136/heart.89.11.1363 · Cited by 958 · cited 1×
“In addition, there were apparent cases in the FDA database for which preclinical studies were negative and the thorough QT studies were positive, and this led to different possible interpretations: (1) The absence of an effect by preclinical testing does not exclude the possibility of a thorough QT study to be positiv…”
BackgroundElectrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties
Antzelevitch, C., Belardinelli, L., Zygmunt, A. C., Burashnikov, A., Di Diego, J. M., Fish, J. M., Cordeiro, J. M., & Thomas, G. (2004) · Circulation · doi:10.1161/01.cir.0000139333.83620.5d · Cited by 675
Terfenadine-Ketoconazole Interaction: Pharmacokinetic and Electrocardiographic Consequences
Honig, P. K. (1993) · JAMA · doi:10.1001/jama.1993.03500120051025 · Cited by 664
Allelic Variants in Long-QT Disease Genes in Patients With Drug-Associated Torsades de Pointes
Yang, P., Kanki, H., Drolet, B., Yang, T., Wei, J., Viswanathan, P. C., Hohnloser, S. H., Shimizu, W., Schwartz, P. J., Stanton, M., et al. (2002) · Circulation · doi:10.1161/01.cir.0000014448.19052.4c · Cited by 554
Evaluation of Drug-Induced QT Interval Prolongation: Implications for Drug Approval and Labelling
Malik, M., & Camm, A. J. (2001) · Drug Safety · doi:10.2165/00002018-200124050-00001 · Cited by 273
Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes
DARPO, B. (2001) · European Heart Journal Supplements · doi:10.1016/s1520-765x(01)90009-4 · Cited by 205
Self-citationAntiarrhythmic Effects of Ranolazine in a Guinea Pig in Vitro Model of Long-QT Syndrome
Wu, L., Shryock, J. C., Song, Y., Li, Y., Antzelevitch, C., & Belardinelli, L. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.066100 · Cited by 193
WEISSENBURGER, J., Nesterenko, V. V., & Antzelevitch, C. N. (2000) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2000.tb01798.x · Cited by 156
Démolis, J. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.111482 · Cited by 155
The influence of cisapride and clarithromycin on QT intervals in healthy volunteers
van Haarst, A. D., Klooster, G. A. E. V. '., van Gerven, J., Schoemaker, R. C., van Oene, J. C., Burggraaf, J., Coene, M. C., & Cohen, A. F. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90137-0 · Cited by 153
Effects of three fluoroquinolones on QT interval in healthy adults after single doses
Noel, G. J., Natarajan, J., Chien, S., Hunt, T. L., Goodman, D. B., & Abels, R. I. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00009-2 · Cited by 153
Pratt, C. M., Ruberg, S., Morganroth, J., McNutt, B., Woodward, J., Harris, S., Ruskin, J., & Moyé, L. (1996) · American Heart Journal · doi:10.1016/s0002-8703(96)90525-6 · Cited by 142
Electrophysiologic Properties and Antiarrhythmic Actions of a Novel Antianginal Agent
Antzelevitch, C. N., Belardinelli, L., Wu, L., Fraser, H. I., Zygmunt, A. C., Burashnikov, A., Diego, J. M. D., Fish, J. M., Cordeiro, J. M., Goodrow, R. J., et al. (2004) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840400900106 · Cited by 129
Shah, R. R. (2002) · Fundamental and Clinical Pharmacology · doi:10.1046/j.1472-8206.2002.00083.x · Cited by 76
Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride
Kivistö, K. T., Lilja, J. J., Backman, J. T., & Neuvonen, P. J. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70007-x · Cited by 74
Patterson, S. D. (2005) · Drug Information Journal · doi:10.1177/009286150503900304 · Cited by 66
Drug‐induced prolongation of the QT interval: why the regulatory concern?
Shah, R. R. (2002) · Fundamental and Clinical Pharmacology · doi:10.1046/j.1472-8206.2002.00082.x · Cited by 46
Computer‐Based Analysis of Dynamic QT Changes: Toward High Precision and Individual Rate Correction
Dota, C., Skallefell, B., Edvardsson, N. G., & Fager, G. (2002) · Annals of Noninvasive Electrocardiology · doi:10.1111/j.1542-474x.2002.tb00177.x · Cited by 25
Cited by
van Gerven, J., & Bonelli, M. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13550 · Cited by 162
Measurement in clinical trials: A neglected issue for statisticians?
Senn, S., & Julious, S. (2009) · Statistics in Medicine · doi:10.1002/sim.3603 · Cited by 136
Shah, S. A., Szeto, A. H., Farewell, R., Shek, A., Fan, D., Quach, K. N., Bhattacharyya, M., Elmiari, J., Chan, W., O'Dell, K., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011318 · Cited by 111
Novodvorsky, P., Bernjak, A., Chow, E., Iqbal, A., Sellors, L., Williams, S., Fawdry, R. A., Parekh, B., Jacques, R. M., Marques, J. L. B., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2177 · Cited by 111
Metadata
- Authors
- Sager, P. T., Nebout, T., & Darpo, B.
- Venue
- Drug Information Journal
- Published
- 2005-10
- Volume
- 39
- Issue
- 4
- Pages
- 387-394
- ISSN
- 0092-8615 (ISSN-L)
- 2164-9200
- OpenAlex
- W1970333224
- Cited by
- 382
- References
- 22
- FWCI
- 9.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.